CMR Surgical to receive $400M strategic investment from Stryker

What's the deal? On 12 October 2026, CMR Surgical and Stryker announced a strategic alliance under which Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical, subject to customary closing conditions. The investment grants Stryker an exclusive option to acquire 100% of CMR Surgical's outstanding equity and makes Stryker the exclusive US sales agent for the Versius portfolio. Andy Pierce, Group President, Medsurg and Neurotechnology at Stryker, is set to join CMR Surgical's board of directors.

Why it matters: The deal gives Stryker an entry into soft-tissue robotic surgery, a segment where it had not previously competed, and gives CMR Surgical, the Cambridge-based maker of the modular Versius surgical robot, access to Stryker's US commercial network to accelerate its US launch. CMR Surgical will continue to lead Versius development and commercialisation outside the US, with R&D remaining in Cambridge and manufacturing at its Ely facility. Versius is described as the second most widely used soft-tissue surgical robot worldwide, with more than 50,000 operations performed in over 35 countries and adoption across more than 20 UK NHS trusts. Cambridge Innovation CapitalDealroom has a profile for this one. Try Dealroom →, CMR's first institutional investor, has backed the company in every funding round since its 2016 Series A.

Read more: Stryker press release · Cambridge Innovation Capital